Archive | 2019
Evaluation of Diabetic Nephropathy using Endogenous Plant Portulaca grandiflora Extract in Alloxan Induced Diabetic Rats
Abstract
Article history: Received 23 September 2019 Accepted 18 October 2019 Available online 21 October 2019 The aim of the study is to prevent nephropathy by using endogenous plant extract Portulaca grandiflora in alloxan induced diabetic rats. Albino rats weighing 150-200 g were divided into 4 groups, each group consists of 4 rats. The alloxan monohydrate (ip. 150 mg/kg) was used for induction of diabetes. After 2 days, fasting blood sugar was assessed and rats with FBS >250 mg/dL were considered as diabetic. After 1 week of alloxan injection the blood urea, creatinine, glucose and uric acid were determined for confirmation of nephropathy. Then these animals were treated with Portulaca grandiflora plant extract. The glimepiride (2 mg/kg) was used as standard drug. After a single dose of alloxan monohydrate blood samples were collected on initial and 7th day from all the rats and levels of glucose, urea, uric acid and creatinine were examined. Then animals were scarified and kidney tissue of control, inducing test, standard groups are examined by histopathology. The results given away that oral administration of Portulaca grandiflora plant extract (100 mg/kg and 200 mg/kg) was significantly reduces the levels of glucose, uric acid, creatinine, urea in diabetic rats. This study revealed that the Portulaca grandiflora is useful in treating diabetes and having minimizing activity of complication diabetic nephropathy by its anti-oxidant activity. Further research is required for better results for diabetic complications.